Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy

by Dr. Julie Nonnekens, Erasmus MC

This talk describes the extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. In vivo imaging was performed on the MILabs VECTorCT imaging platform.

Took place: November, 2020

CT,PET,SPECT

You may also like

Bart Cornelissen imaging DNA damage webinar thumbnail
Imaging DNA damage
CT,PET,SPECT
Each DNA damage repair pathway leads to the recruitment, upregulation, or activation of specific proteins within the nucleus, which, in some cases, can represent attractive targets for molecular imaging.
Fabian Kiessling webinar thumbnail
Quantitative hybrid fluorescence and CT to assess drug biodistribution in cancer research
CT,Optical
For a detailed biodistribution analysis, PET and SPECT are usually preferred as they are more accurate and quantitative, so the question is, can optical imaging become a complementary tool for pre-clinical biodistribution analysis.
webinar thumnail Marko Rosenholm
Dynamic SPECT/CT imaging of glymphatic drug delivery and clearance in small animals
CT,SPECT
Marko Rosenholm presents some of the findings and results regarding dynamic SPECT/CT imaging of a glymphatic system they have acquired with the MILabs VECTor/CT system.

Global Sales, Service & Support

Duwboot 7a
3991 CD  Houten
The Netherlands

Phone: +31 85 088 5753
Fax: +31 88 756 0094
E-mail: [email protected]
REQUEST MORE INFORMATION

Distributors

MILabs products are used in more than 65 countries and are supported by a global network of distributors and factory trained support engineers.

Please contact MILabs directly for more information about your local MILabs business partner.

Scroll to Top